Stockreport

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 [Yahoo! Finance]

Traws Pharma, Inc.  (TRAW) 
PDF and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment Separate single-arm trial assessing safety and efficacy in PAXLOVID ® -i [Read more]